AMGN · News · 20261104N

Guidance and Outlook

AMGEN INC · 2026-11-04 · Importance 63 · Surprise 60 · In source text

Amgen raised its 2026 revenue guidance to $38.9 billion–$39.7 billion and non-GAAP earnings guidance to $22.90–$23.70 per share. Management maintained its expected full-year non-GAAP operating margin at 45%–46% of product sales. The CFO cautioned that operating expenses should increase sequentially in the fourth quarter.

Key facts

• Amgen's full-year revenue midpoint was raised to $39.3 billion and its non-GAAP EPS midpoint to $23.30. source
• Amgen raised 2026 revenue guidance to $38.9 billion to $39.7 billion. source
• Amgen raised 2026 non-GAAP EPS guidance to $22.90 to $23.70. source
• Amgen's Q3 2026 revenue was $10.37 billion, GAAP net income was $3.86 billion, and full-year guidance was raised to $38.9 billion to $39.7 billion of revenue and GAAP EPS of $18.34 to $19.28. source
• Amgen raised 2026 revenue guidance to $38.9 billion-$39.7 billion and non-GAAP earnings guidance to $22.90-$23.70 per share. source
• Amgen reported Q3 2026 non-GAAP EPS growth of 14% and management raised full-year guidance for revenue and non-GAAP EPS. source
• Amgen reported positive Phase 3 data for IMDELLTRA, TEZSPIRE and dazodalibep. source
• Amgen anticipates filling sales gaps with multiple new drug candidates that recently showed positive late-stage clinical data. source

Impact estimates